Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endocrinology
Biotech
Ascendis scores in phase 3 trial, a boost to endocrine portfolio
Ascendis Pharma has its eyes on an NDA application this year after checking off top endpoints in a phase 3 hypoparathyroidism trial of TransCon PTH.
Max Bayer
Mar 14, 2022 11:15am
New phase 3 data paint fuller picture for Horizon's teprotumumab
Apr 26, 2019 2:05pm
Apitope preps Graves’ disease drug for phase 2
Apr 16, 2018 10:40am
Crinetics raises $63.5M for oral acromegaly therapy
Mar 14, 2018 9:10am
